194 related articles for article (PubMed ID: 19064988)
21. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors and breast cancer.
Macedo LF; Sabnis G; Brodie A
Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202
[TBL] [Abstract][Full Text] [Related]
23. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
27. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
29. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Turnbull AK; Arthur LM; Renshaw L; Larionov AA; Kay C; Dunbier AK; Thomas JS; Dowsett M; Sims AH; Dixon JM
J Clin Oncol; 2015 Jul; 33(20):2270-8. PubMed ID: 26033813
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
[TBL] [Abstract][Full Text] [Related]
31. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
33. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
34. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M
Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541
[TBL] [Abstract][Full Text] [Related]
35. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
36. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
37. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):348-9. PubMed ID: 24674874
[TBL] [Abstract][Full Text] [Related]
38. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic observations in MCF-7 aromatase xenografts.
Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]